CF PharmTech, Inc. (CF PHARMTECH) Aktie

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China.